Skip to main content
Erschienen in:

23.03.2020 | Original Article

Clinical outcomes and prognostic factors associated with internal ureteral stent placement for malignant extrinsic ureteral obstruction

verfasst von: Hiroshi Matsuura, Shigeki Arase, Yasuhide Hori

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The optimal management of malignant extrinsic ureteral obstruction (MUO) remains unclear. It is necessary to assess the patient prognosis in deciding the adaptation of drainage of renal pelvis. In this study, we investigated the clinical outcomes after ureteral stenting for MUO and the predictive factors for overall survival in order to create a risk-stratification model.

Methods

We retrospectively analyzed the clinical and laboratory data of 93 patients with radiologically significant hydronephrosis associated with MUO who underwent successful stent placement between May 2005 and May 2018.

Results

The median survival duration after the initial stent insertion was 266 days. Of the 93 patients, 70 died, and the median interval from the first stent insertion to death was 160 days. Multivariate analysis showed that gastric cancer as the primary disease, poor performance status before stenting, and treatment after stent insertion were significant predictors of survival. According to these three factors, we stratified patients into the following four prognostic groups: no-factor (43 patients), one-factor (23 patients), two-factor (23 patients), and three-factor (4 patients) groups. This classification was effective for predicting survival, and the median survival durations in these groups were 807, 269, 44, and 12 days, respectively (p < 0.001).

Conclusions

Our stratification model of patients with a poor prognosis after ureteral stent placement for MUO may allow urologists and clinicians to identify patients who will benefit from ureteral stenting.
Literatur
1.
Zurück zum Zitat Turgut B, Bayraktar AM, Bakdık S, Hamarat MB, Öncü F, Gönen M, Tolu I (2019) Placement of double-J stent in patients with malignant ureteral obstruction: antegrade or retrograde approach? Clin Radiol 19:30379–30374 Turgut B, Bayraktar AM, Bakdık S, Hamarat MB, Öncü F, Gönen M, Tolu I (2019) Placement of double-J stent in patients with malignant ureteral obstruction: antegrade or retrograde approach? Clin Radiol 19:30379–30374
2.
Zurück zum Zitat Allen DJ, Longhorn SE, Philp T, Smith RD, Choong S (2010) Percutaneous urinary drainage and ureteric stenting in malignant disease. Clin Oncol 22:733–739CrossRef Allen DJ, Longhorn SE, Philp T, Smith RD, Choong S (2010) Percutaneous urinary drainage and ureteric stenting in malignant disease. Clin Oncol 22:733–739CrossRef
3.
Zurück zum Zitat Pavlovic K, Lange D, Chew BH (2016) Stents for malignant ureteral obstruction. Asian J Urol 3:142–149CrossRef Pavlovic K, Lange D, Chew BH (2016) Stents for malignant ureteral obstruction. Asian J Urol 3:142–149CrossRef
4.
Zurück zum Zitat Sountoulides P, Mykoniatis I, Dimasis N (2014) Palliative management of malignant upper urinary tract obstruction. Hippokratia. 18:292–297PubMedPubMedCentral Sountoulides P, Mykoniatis I, Dimasis N (2014) Palliative management of malignant upper urinary tract obstruction. Hippokratia. 18:292–297PubMedPubMedCentral
5.
Zurück zum Zitat Elsamra SE, Leavitt DA, Motato HA, Friedlander JI, Siev M, Keheila M, Hoenig DM, Smith AD, Okeke Z (2015) Stenting for malignant ureteral obstruction: tandem, metal or metal-mesh stents. Int J Urol 22:629–636CrossRef Elsamra SE, Leavitt DA, Motato HA, Friedlander JI, Siev M, Keheila M, Hoenig DM, Smith AD, Okeke Z (2015) Stenting for malignant ureteral obstruction: tandem, metal or metal-mesh stents. Int J Urol 22:629–636CrossRef
6.
Zurück zum Zitat Ganatra AM, Loughlin KR (2005) The management of malignant ureteral obstruction treated with ureteral stents. J Urol 174:2125–2128CrossRef Ganatra AM, Loughlin KR (2005) The management of malignant ureteral obstruction treated with ureteral stents. J Urol 174:2125–2128CrossRef
7.
Zurück zum Zitat Kamiyama Y, Matsuura S, Kato M, Abe Y, Takyu S, Yoshikawa K, Arai Y (2011) Stent failure in the man-agement of malignant extrinsic ureteral obstruction: risk factors. Int J Urol 18:379–382CrossRef Kamiyama Y, Matsuura S, Kato M, Abe Y, Takyu S, Yoshikawa K, Arai Y (2011) Stent failure in the man-agement of malignant extrinsic ureteral obstruction: risk factors. Int J Urol 18:379–382CrossRef
8.
Zurück zum Zitat Yossepowitch O, Lifshitz DA, Dekel Y, Gross M, Keidar DM, Neuman M, Livne PM, Baniel J (2001) Predicting the success of retrograde stenting for managing ureteral obstruction. J Urol 66:1746–1749CrossRef Yossepowitch O, Lifshitz DA, Dekel Y, Gross M, Keidar DM, Neuman M, Livne PM, Baniel J (2001) Predicting the success of retrograde stenting for managing ureteral obstruction. J Urol 66:1746–1749CrossRef
9.
Zurück zum Zitat Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRef Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRef
10.
Zurück zum Zitat Ishioka J, Kageyama Y, Inoue M, Higashi Y, Kihara K (2008) Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases. J Urol 180:618–621CrossRef Ishioka J, Kageyama Y, Inoue M, Higashi Y, Kihara K (2008) Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases. J Urol 180:618–621CrossRef
11.
Zurück zum Zitat Cordeiro MD, Coelho RF, Chade DC, Pessoa RR, Chaib MS, Colombo-Júnior JR, Pontes-Júnior J, Guglielmetti GB, Srougi M (2016) A prognostic model for survival after palliative urinary diversion for malignant ureteric obstruction: a prospective study of 208 patients. BJU Int 117:266–271CrossRef Cordeiro MD, Coelho RF, Chade DC, Pessoa RR, Chaib MS, Colombo-Júnior JR, Pontes-Júnior J, Guglielmetti GB, Srougi M (2016) A prognostic model for survival after palliative urinary diversion for malignant ureteric obstruction: a prospective study of 208 patients. BJU Int 117:266–271CrossRef
12.
Zurück zum Zitat Alawneh A, Tuqan W, Innabi A, Al-Nimer Y, Azzouqah O, Rimawi D, Taqash A, Elkhatib M, Klep-stad P (2016) Clinical factors associated with a short survival time after percutaneous nephrostomy for ureteric obstruction in cancer patients: an updated model. J Pain Symptom Manag 251:255–261CrossRef Alawneh A, Tuqan W, Innabi A, Al-Nimer Y, Azzouqah O, Rimawi D, Taqash A, Elkhatib M, Klep-stad P (2016) Clinical factors associated with a short survival time after percutaneous nephrostomy for ureteric obstruction in cancer patients: an updated model. J Pain Symptom Manag 251:255–261CrossRef
13.
Zurück zum Zitat Azuma T, Nagase Y, Oshi M (2013) Prognostic marker for patients with malignant ureter obstruction. Clin Genitourin Cancer 11:353–356CrossRef Azuma T, Nagase Y, Oshi M (2013) Prognostic marker for patients with malignant ureter obstruction. Clin Genitourin Cancer 11:353–356CrossRef
14.
Zurück zum Zitat Song Y, Fei X, Song Y (2012) Percutaneous nephrostomy versus indwelling ureteral stent in the management of gynecological malignancies. Int J Gynecol Cancer 22:697–702CrossRef Song Y, Fei X, Song Y (2012) Percutaneous nephrostomy versus indwelling ureteral stent in the management of gynecological malignancies. Int J Gynecol Cancer 22:697–702CrossRef
15.
Zurück zum Zitat Lienert A, Ing A, Mark S (2009) Prognostic factors in malignant ureteric obstruction. BJU Int 104:938–941CrossRef Lienert A, Ing A, Mark S (2009) Prognostic factors in malignant ureteric obstruction. BJU Int 104:938–941CrossRef
16.
Zurück zum Zitat Jeong IG, Han KS, Joung JY, Seo HK, Chung J (2007) The outcome with ureteric stents for managing non-urological malignant ureteric obstruction. BJU Int 100:1288–1291CrossRef Jeong IG, Han KS, Joung JY, Seo HK, Chung J (2007) The outcome with ureteric stents for managing non-urological malignant ureteric obstruction. BJU Int 100:1288–1291CrossRef
17.
Zurück zum Zitat Ohtaka M, Kawahara T, Takamoto D, Mochizuki T, Hattori Y, Teranishi J, Makiyama K, Miyoshi Y, Yumura Y, Yao M, Uemura H (2018) Gastrointestinal cancer and bilateral hydronephrosis resulted in a high risk of ureteral stent failure. BMC Urol 18:35CrossRef Ohtaka M, Kawahara T, Takamoto D, Mochizuki T, Hattori Y, Teranishi J, Makiyama K, Miyoshi Y, Yumura Y, Yao M, Uemura H (2018) Gastrointestinal cancer and bilateral hydronephrosis resulted in a high risk of ureteral stent failure. BMC Urol 18:35CrossRef
18.
Zurück zum Zitat Migita K, Watanabe A, Samma S, Ohyama T, Ishikawa H, Kagebayashi Y (2011) Clinical outcome and management of ureteral obstruction secondary to gastric cancer. World J Surg 35:1035–1041CrossRef Migita K, Watanabe A, Samma S, Ohyama T, Ishikawa H, Kagebayashi Y (2011) Clinical outcome and management of ureteral obstruction secondary to gastric cancer. World J Surg 35:1035–1041CrossRef
19.
Zurück zum Zitat Kulkarni R (2014) Metallic stents in the management of ureteric strictures. Indian J Urol 30:65–72CrossRef Kulkarni R (2014) Metallic stents in the management of ureteric strictures. Indian J Urol 30:65–72CrossRef
20.
Zurück zum Zitat Wang JY, Zhang HL, Zhu Y, Qin XJ, Dai BO, Ye DW (2016) Predicting the failure of retrograde ureteral stent insertion for managing malignant ureteral obstruction in outpatients. Oncol Lett 11:879–883CrossRef Wang JY, Zhang HL, Zhu Y, Qin XJ, Dai BO, Ye DW (2016) Predicting the failure of retrograde ureteral stent insertion for managing malignant ureteral obstruction in outpatients. Oncol Lett 11:879–883CrossRef
21.
Zurück zum Zitat Baumgarten AS, Hakky TS, Carrion RE, Lockhart JL, Spiess PE (2014) A single-institution experience with metallic ureteral stents: a cost-effective method of managing deficiencies in ureteral drainage. Int Braz J Urol 40:225–231CrossRef Baumgarten AS, Hakky TS, Carrion RE, Lockhart JL, Spiess PE (2014) A single-institution experience with metallic ureteral stents: a cost-effective method of managing deficiencies in ureteral drainage. Int Braz J Urol 40:225–231CrossRef
22.
Zurück zum Zitat Zita Ficko and Elias S. Hyams (2018) Complications of upper tract drainage. in: Samir S. Taneja MD and Ojas Shah MD (ed) Complications of urologic surgery, 5th. Elsevier, New York, pp 218–225 Zita Ficko and Elias S. Hyams (2018) Complications of upper tract drainage. in: Samir S. Taneja MD and Ojas Shah MD (ed) Complications of urologic surgery, 5th. Elsevier, New York, pp 218–225
23.
Zurück zum Zitat Khoo CC, Abboudi H, Cartwright R, El-Husseiny T, Dasgupta R (2018) Metallic ureteric stents in malignant ureteric obstruction: a systematic review. Urology 118:12–20CrossRef Khoo CC, Abboudi H, Cartwright R, El-Husseiny T, Dasgupta R (2018) Metallic ureteric stents in malignant ureteric obstruction: a systematic review. Urology 118:12–20CrossRef
Metadaten
Titel
Clinical outcomes and prognostic factors associated with internal ureteral stent placement for malignant extrinsic ureteral obstruction
verfasst von
Hiroshi Matsuura
Shigeki Arase
Yasuhide Hori
Publikationsdatum
23.03.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2020
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-020-05413-0

Neu im Fachgebiet Onkologie

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Knochenmarktransplantat als Chance für ältere AML-Patienten

Lange Zeit ist die Transplantation von hämatopoetischen Stammzellen nur bei jüngeren Patienten mit akuter myeloischer Leukämie praktiziert worden. Inzwischen profitieren auch Ältere davon. Ergebnisse einer Studie unterstützen dieses Vorgehen.

Nierenzellkarzinom: Kein Nachteil durch subkutan appliziertes Nivolumab

Die subkutane Applikation von Nivolumab ist nach Daten einer Phase-3-Studie ähnlich gut wirksam wie die intravenöse: Die Pharmakokinetik ist vergleichbar, die objektive Response war in der Studie sogar leicht besser als in der Gruppe mit Infusionen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.